BR112013023266B8 - inibidores da girase tricíclicos - Google Patents

inibidores da girase tricíclicos

Info

Publication number
BR112013023266B8
BR112013023266B8 BR112013023266A BR112013023266A BR112013023266B8 BR 112013023266 B8 BR112013023266 B8 BR 112013023266B8 BR 112013023266 A BR112013023266 A BR 112013023266A BR 112013023266 A BR112013023266 A BR 112013023266A BR 112013023266 B8 BR112013023266 B8 BR 112013023266B8
Authority
BR
Brazil
Prior art keywords
gyrase inhibitors
tricyclic gyrase
tricyclic
compounds
inhibitors
Prior art date
Application number
BR112013023266A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112013023266A8 (pt
BR112013023266B1 (pt
BR112013023266A2 (https=
Inventor
Bensen Daniel
W Phillipson Douglas
Lightstone Felice
Finn John
Zhang Junhu
William Tari Leslie
Jung Michael
Trzoss Michael
Aristoff Paul
E Wong Sergio
Joong Lee Suk
To Lam Thanh
B Nguyen Toan
Li Xiaoming
Chen Zhiyong
Original Assignee
L Livermore Nat Security Llc
Merck Sharp & Dohme
Trius Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L Livermore Nat Security Llc, Merck Sharp & Dohme, Trius Therapeutics Inc filed Critical L Livermore Nat Security Llc
Publication of BR112013023266A2 publication Critical patent/BR112013023266A2/pt
Publication of BR112013023266A8 publication Critical patent/BR112013023266A8/pt
Publication of BR112013023266B1 publication Critical patent/BR112013023266B1/pt
Publication of BR112013023266B8 publication Critical patent/BR112013023266B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112013023266A 2011-03-15 2012-03-14 inibidores da girase tricíclicos BR112013023266B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161453011P 2011-03-15 2011-03-15
US61/453,011 2011-03-15
PCT/US2012/029104 WO2012125746A1 (en) 2011-03-15 2012-03-14 Tricyclic gyrase inhibitors

Publications (4)

Publication Number Publication Date
BR112013023266A2 BR112013023266A2 (https=) 2017-09-12
BR112013023266A8 BR112013023266A8 (pt) 2018-06-12
BR112013023266B1 BR112013023266B1 (pt) 2020-12-29
BR112013023266B8 true BR112013023266B8 (pt) 2021-04-06

Family

ID=45879060

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013023266A BR112013023266B8 (pt) 2011-03-15 2012-03-14 inibidores da girase tricíclicos

Country Status (16)

Country Link
US (2) US9732083B2 (https=)
EP (1) EP2686320B1 (https=)
JP (1) JP6140083B2 (https=)
KR (2) KR20140059164A (https=)
CN (1) CN103562208B (https=)
AR (1) AR085806A1 (https=)
AU (1) AU2012229997B2 (https=)
BR (1) BR112013023266B8 (https=)
CA (1) CA2829939C (https=)
IL (1) IL228220A (https=)
MX (1) MX345780B (https=)
PH (1) PH12013501800A1 (https=)
RU (1) RU2626979C2 (https=)
TW (1) TWI527818B (https=)
WO (1) WO2012125746A1 (https=)
ZA (1) ZA201307583B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2686320B1 (en) * 2011-03-15 2016-05-18 Merck Sharp & Dohme Corp. Tricyclic gyrase inhibitors
EP2807165B1 (en) * 2012-01-27 2019-05-15 Université de Montréal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
CN105189505B (zh) * 2012-09-12 2019-03-22 默克夏普&多梅有限公司 用作抗菌剂的三环促旋酶抑制剂
CN103304488B (zh) * 2013-06-13 2015-12-09 暨明医药科技(苏州)有限公司 光学纯2-(1-羟基乙基)-5-羟基嘧啶的制备方法
CN105899511B (zh) * 2013-09-11 2019-06-07 默沙东公司 三环促旋酶抑制剂
US20170007615A1 (en) 2014-02-03 2017-01-12 Biota Europe Ltd Antibacterial Compounds
WO2015150337A1 (en) * 2014-04-01 2015-10-08 Amakem Nv Lim kinase inhibitors
CA3057431A1 (en) 2017-03-24 2018-09-27 Taisho Pharmaceutical Co., Ltd. 2(1h)-quinolinone derivative
CN110475777B (zh) * 2017-03-30 2022-04-15 豪夫迈·罗氏有限公司 用于治疗和预防细菌感染的新吡啶并[2,3-b]吲哚化合物
CN108504647B (zh) * 2018-03-09 2021-11-05 中山大学 一种dna促旋酶的药物结合口袋及其应用
JP7296992B2 (ja) * 2018-05-28 2023-06-23 エフ. ホフマン-ラ ロシュ アーゲー 細菌感染症の処置および予防のための新規オキソキノリジン化合物
WO2020064661A1 (en) * 2018-09-26 2020-04-02 F. Hoffmann-La Roche Ag Substituted pyridoindoles for the treatment and prophylaxis of bacterial infection
EP3887370B1 (en) * 2018-11-27 2023-01-18 F. Hoffmann-La Roche AG Tricyclic compounds for the treatment and prophylaxis of bacterial infection
WO2020109191A1 (en) 2018-11-27 2020-06-04 F. Hoffmann-La Roche Ag Aryl compounds for the treatment and prophylaxis of bacterial infection
WO2020127624A1 (en) 2018-12-20 2020-06-25 F. Hoffmann-La Roche Ag Oxopyrido[1,2-a]pyrimidine compounds for the treatment and prophylaxis of bacterial infection
CN114763357B (zh) * 2021-01-15 2024-06-18 中国科学院上海药物研究所 吲哚并嘧啶三环类化合物及其制备方法和用途

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN157280B (https=) 1983-07-15 1986-02-22 Hoechst India
CA1336090C (en) 1988-08-31 1995-06-27 Isao Hayakawa Spiro-substituted cyclic amines of quinolone derivatives
DE4030059A1 (de) 1990-09-22 1992-03-26 Bayer Ag Verfahren zur herstellung von 5-hydroxy-3,4,5,6-tetrahydro-pyrimidin-derivaten
DE4032560A1 (de) 1990-10-13 1992-04-16 Bayer Ag 7-(2,7-diazabicyclo(3.3.0)octyl)-3-chinolon- und -naphtyridoncarbonsaeure-derivate
ES2150941T3 (es) 1992-04-03 2000-12-16 Upjohn Co Aminas biciclicas-heterociclicas eficaces farmaceuticamente.
US5279359A (en) 1992-06-26 1994-01-18 Erickson Donald C Rotary trisorption heat pump
US5350791A (en) 1992-07-02 1994-09-27 Henkel Corporation Hydrophilicizing treatment for metal objects
US5527910A (en) 1992-12-30 1996-06-18 Cheil Foods & Chemicals, Inc. Pyridone carboxylic acid compounds and their uses for treating infectious diseases caused by bacteria
RU2158127C2 (ru) * 1994-12-23 2000-10-27 Варнер-Ламберт Компани Способы ингибирования тирозинкиназы рецептора эпидермального фактора роста, азотсодержащие трициклические соединения, фармацевтическая композиция, предназначенная для введения ингибитора тирозинкиназы рецептора эпидермального фактора роста, например, erb-b2, erb-b3 или erb-b4, и противозачаточная композиция
NZ304519A (en) 1995-03-02 2000-01-28 Upjohn Co Pydrimido[4,5-b]indoles
SI9620103A (sl) * 1995-07-06 1998-10-31 Novartis Ag Pirolopirimidini in postopki za njihovo pripravo
WO1998029397A1 (en) 1996-12-27 1998-07-09 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyrimidine compounds and medicinal use thereof
SI0964865T1 (en) 1997-01-08 2003-08-31 Pharmacia & Upjohn Company Pharmaceutically active tricyclic amines
ATE265847T1 (de) 1997-07-29 2004-05-15 Upjohn Co Selbstemulgierbare formulierung enthaltend lipophile verbindungen
US6147085A (en) 1999-04-01 2000-11-14 Neurogen Corporation Aminoalkyl substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives
EP1068207A1 (en) 1998-04-02 2001-01-17 Neurogen Corporation AMINOALKYL SUBSTITUTED 9H-PYRIDINO 2,3-b]INDOLE AND 9H-PYRIMIDINO 4,5-b]INDOLE DERIVATIVES
US6221875B1 (en) 1998-04-02 2001-04-24 Neurogen Corporation Substituted 9H-pyridino [2,3-B]indole and 9H-pyrimidino [4,5-B]indole derivatives: selective neuropeptide Y receptor ligands
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
WO2000066585A1 (en) 1999-04-30 2000-11-09 Neurogen Corporation 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
SK10572002A3 (sk) 2000-01-24 2003-10-07 Warner-Lambert Company 3-Aminochinazolín-2,4-diónové antibakteriálne činidlá
FR2816509B1 (fr) 2000-11-15 2004-02-06 Sod Conseils Rech Applic Association d'inhibiteurs de calpaine et de piegeurs des formes reactives de l'oxygene
JP2005515173A (ja) 2001-10-31 2005-05-26 バイエル・ヘルスケア・アクチェンゲゼルシャフト ピリミド[4,5−b]インドール誘導体
CA2466266A1 (en) * 2001-11-08 2003-07-31 Antex Pharma, Inc. Novel substituted alkane compounds and uses thereof
WO2003057149A2 (en) 2001-12-28 2003-07-17 Bayer Corporation 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones
TWI270549B (en) 2002-12-26 2007-01-11 Taisho Pharmaceutical Co Ltd Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
WO2004058764A1 (en) * 2002-12-27 2004-07-15 Bayer Healthcare Ag 4-phenyl-pyrimido [4,5-b] indole derivatives
JP4845736B2 (ja) 2003-10-14 2011-12-28 アリゾナ ボード オブ リージェンツ オン ビハーフ ザ ユニバーシティー オブ アリゾナ プロテインキナーゼ阻害剤
US20090143399A1 (en) 2003-10-14 2009-06-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US20080051414A1 (en) 2003-10-14 2008-02-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
JP2006036762A (ja) 2004-06-25 2006-02-09 Taisho Pharmaceut Co Ltd 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
JP2007161585A (ja) 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
WO2008007113A2 (en) 2006-07-14 2008-01-17 Astex Therapeutics Limited Pharmaceutical combinations
CA2604284A1 (en) 2005-04-28 2006-11-02 Supergen, Inc. Protein kinase inhibitors
EP1749822B1 (en) * 2005-08-05 2008-10-15 Hybrigenics S.A. Novel cysteine protease inhibitors and their therapeutic applications
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
JP2007169216A (ja) 2005-12-22 2007-07-05 Taisho Pharmaceut Co Ltd 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
US20080207632A1 (en) 2006-10-31 2008-08-28 Supergen, Inc. Protein kinase inhibitors
US8618121B2 (en) 2007-07-02 2013-12-31 Cancer Research Technology Limited 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors
US7982035B2 (en) 2007-08-27 2011-07-19 Duquesne University Of The Holy Spirit Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
US7960400B2 (en) * 2007-08-27 2011-06-14 Duquesne University Of The Holy Ghost Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
WO2009091476A1 (en) 2008-01-14 2009-07-23 Irm Llc Compositions and methods for treating cancers
ATE546448T1 (de) * 2008-08-02 2012-03-15 Janssen Pharmaceutica Nv Urotensin-ii-rezeptorantagonisten
WO2011056739A1 (en) 2009-11-03 2011-05-12 Glaxosmithkline Llc Compounds and methods
EP2686320B1 (en) * 2011-03-15 2016-05-18 Merck Sharp & Dohme Corp. Tricyclic gyrase inhibitors
CN105189505B (zh) * 2012-09-12 2019-03-22 默克夏普&多梅有限公司 用作抗菌剂的三环促旋酶抑制剂
CN105899511B (zh) * 2013-09-11 2019-06-07 默沙东公司 三环促旋酶抑制剂
WO2016067009A1 (en) * 2014-10-28 2016-05-06 Redx Pharma Plc Compounds with activity against bacteria and mycobacteria

Also Published As

Publication number Publication date
WO2012125746A1 (en) 2012-09-20
IL228220A0 (en) 2013-11-25
BR112013023266A8 (pt) 2018-06-12
MX2013010511A (es) 2014-03-27
RU2013140798A (ru) 2015-04-20
IL228220A (en) 2017-04-30
CN103562208B (zh) 2016-08-31
CN103562208A (zh) 2014-02-05
AU2012229997A1 (en) 2013-09-19
EP2686320A1 (en) 2014-01-22
AU2012229997B2 (en) 2016-04-14
MX345780B (es) 2017-02-15
KR102132574B1 (ko) 2020-07-09
EP2686320B1 (en) 2016-05-18
CA2829939C (en) 2020-10-13
NZ614983A (en) 2016-07-29
US10858360B2 (en) 2020-12-08
PH12013501800A1 (en) 2013-10-14
KR20140059164A (ko) 2014-05-15
TWI527818B (zh) 2016-04-01
ZA201307583B (en) 2014-08-27
JP2014508173A (ja) 2014-04-03
BR112013023266B1 (pt) 2020-12-29
RU2626979C2 (ru) 2017-08-02
US20120238751A1 (en) 2012-09-20
AR085806A1 (es) 2013-10-30
WO2012125746A9 (en) 2013-10-24
BR112013023266A2 (https=) 2017-09-12
TW201245200A (en) 2012-11-16
JP6140083B2 (ja) 2017-05-31
CA2829939A1 (en) 2012-09-20
KR20190104632A (ko) 2019-09-10
US20170369498A1 (en) 2017-12-28
US9732083B2 (en) 2017-08-15

Similar Documents

Publication Publication Date Title
BR112013023266B8 (pt) inibidores da girase tricíclicos
BR112013025387A2 (pt) análogos substituídos da n-fenilpirimidin-2-amina como inibidores da quinase axl
UY33536A (es) INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS
BR112015000106A2 (pt) moduladores heterocíclicos de síntes de lipídio
CR20140464A (es) Compuestos de heterociclilo
CY1120480T1 (el) Ενωσεις πυραζολοπυριμιδινης
BR112012019672A2 (pt) pirrolidina-2-carboxamidas substituídas.
IN2014MN02598A (https=)
BR112016000909A8 (pt) derivados piperidinil indólicos, seus usos, e combinação e composição farmacêuticas
CR20150371A (es) Inhibidores de prmt5 y sus usos
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
CU20130094A7 (es) Moduladores de la vía del complemento
PH12014502733A1 (en) Neprilysin inhibitors
CR20140133A (es) Compuestos de piridazinona y sus usos como inhibidores de daao
UY33731A (es) ?derivados de ácido amino-fenil-pentanoico sustituidos como inhibidores de nep?
WO2014031872A3 (en) Small molecule inhibitors for treating parasitic infections
UY35325A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
CU20130139A7 (es) Derivados glocósidos y usos de los mismos
EP2773346A4 (en) PHARMACEUTICAL COMPOSITIONS OF HYDROPHOBIC CAMPTOTHECIN DERIVATIVES
BR112017000584A2 (pt) inibidores da aldosterona sintase
CR20130318A (es) Nuevos compuestos de benzodioxol-piperazina
BR112014018738A8 (pt) Métodos e intermediários para preparo de agentes farmacêuticos
BR112012007755A2 (pt) profármacos de derivado de piperidinila como moduladores da atividade de receptores de quimiocinas
BR112016005361B8 (pt) Composto, composição, e, uso de um composto
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: TRIUS THERAPEUTICS INC (US) , LAWRENCE LIVERMORE N

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) ; M

B25A Requested transfer of rights approved

Owner name: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) ; M

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) ; M

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2012, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2608 DE 29/12/2020 QUANTO AO INVENTOR.

B25A Requested transfer of rights approved

Owner name: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) ; MERCK SHARP AND DOHME LLC (US)